XRCC4 Antibody (OTI4H9) [DyLight 594]
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-74896DL594
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Immunohistochemistry, Immunohistochemistry-Paraffin
Label
DyLight 594 (Excitation = 593 nm, Emission = 618 nm)
Antibody Source
Monoclonal Mouse IgG1 Clone # OTI4H9
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Full-length protein expressed in 293T cell transfected with human XRCC4 expression vector.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Applications for XRCC4 Antibody (OTI4H9) [DyLight 594]
Application
Recommended Usage
Immunohistochemistry
Optimal dilutions of this antibody should be experimentally determined.
Immunohistochemistry-Paraffin
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Immunogen affinity purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: XRCC4
Alternate Names
complementing defective, repair in Chinese hamster, X-ray repair complementing defective repair in Chinese hamster cells 4, X-ray repair cross-complementing protein 4
Gene Symbol
XRCC4
Additional XRCC4 Products
Product Documents for XRCC4 Antibody (OTI4H9) [DyLight 594]
Product Specific Notices for XRCC4 Antibody (OTI4H9) [DyLight 594]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...